Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma

28 Jun 2023

Abstract excerpt

Significant progress has been made in understanding the pathogenesis of pancreatic ductal adenocarcinoma (PDAC) by generating and using murine models. To accelerate drug discovery by identifying novel therapeutic targets on a systemic level, here we generated a Drosophila model mimicking the genetic signature in PDAC (KRAS, TP53, CDKN2A, and SMAD4 alterations), which is associated with the worst prognosis in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hippo pathway signaling and YAP/TAZ
Share to Microtubule and mitosis dynamics
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37378549
DOI: 10.1158/0008-5472.can-22-3762

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal AdenocarcinomaPMID 37378549Read ↗

Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics PerspectiveSemantic proximity Read ↗

Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors.Semantic proximity Read ↗

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance.Semantic proximity Read ↗

Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma.Semantic proximity Read ↗

KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.Semantic proximity Read ↗

A targeted genetic modifier screen in Drosophila uncovers vulnerabilities in a genetically complex model of colon cancerSemantic proximity Read ↗

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice.Semantic proximity Read ↗

A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.Semantic proximity Read ↗

Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.